Home > Insider Trading > Filing (0000921895-21-001455)

Filing Details

Accession Number:: 0000921895-21-001455
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-21 16:19:09
Reporting Period:: 2021-05-19

Accepted Time:: 2021-05-21 16:19:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1123494	Harvard Bioscience Inc	HBIO	Laboratory Analytical Instruments (3826)	043306140

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1400121	W James Green	C/O Harvard Bioscience, Inc. 84 October Hill Road Holliston MA 01746	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-05-19	39,188	$2.63	2,318,966	No	4	M	Direct
Common Stock	Disposition	2021-05-19	39,188	$7.17	2,279,778	No	4	S	Direct
Common Stock	Acquisiton	2021-05-20	14,876	$2.63	2,294,654	No	4	M	Direct
Common Stock	Disposition	2021-05-20	14,876	$7.03	2,279,778	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2021-05-19	39,188	$0.00	39,188	$2.63
Common Stock	Stock option (right to buy)	Disposition	2021-05-20	14,876	$0.00	14,876	$2.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
391,878		2027-06-11	No	4	M	Direct
377,002		2027-06-11	No	4	M	Direct

Footnotes

Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 685,234 shares of common stock beneficially owned by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $7.07 to $7.26, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes (a) the shares and awards described in footnote (1) above, less (b) the disposition of shares reported in footnote (2) above.
Includes (a) the shares and awards described in footnote (3) above, plus (b) the acquisition of 14,876 shares of common stock pursuant to the exercise of stock options as reported on this Form 4.
This transaction was executed in multiple trades at prices ranging from $7.02 to $7.05, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes (a) the shares and awards described in footnote (4) above, less (b) the disposition of shares reported in footnote (5) above.
The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023.